Next Article in Journal
Palliative Chemotherapy for Patients 70 Years of Age and Older with Metastatic Colorectal Cancer: A Single-Centre Experience
Previous Article in Journal
Pleural Fluid Tumour Markers in Malignant Pleural Effusion with Inconclusive Cytologic Results
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 22
Issue 5
10.3747/co.22.2380
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Physician Preferences for Bone Metastasis Drug Therapy in Canada

by
J. Arellano
1,
J.M. González
2,
Y. Qian
1,
M. Habib
3,
A.F. Mohamed
2,
F. Gatta
4,*,
A.B. Hauber
2,
J. Posner
2,
N. Califaretti
5 and
E. Chow
6
1
Amgen, Thousand Oaks, CA, USA
2
RTI Health Solutions, Research Triangle Park, NC, USA
3
Amgen Canada, Toronto, ON, Canada
4
Amgen Europe, Zug, Switzerland
5
Grand River Regional Cancer Centre, Waterloo, ON, Canada
6
Sunnybrook Health Sciences Centre, Toronto, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2015, 22(5), 342-348; https://doi.org/10.3747/co.22.2380
Submission received: 3 July 2015 / Revised: 6 August 2015 / Accepted: 9 September 2015 / Published: 1 October 2015

Abstract

Background: Currently in Canada, several bone-targeted agents (BTAS) with varying characteristics are available for the prevention of skeletal-related events (SRES) in patients with bone metastasis secondary to solid tumours. In the present study, we evaluated the preferences of physicians in Canada for the various attributes of the available BTAS. Methods: Physicians treating patients with bone metastasis from solid tumours were invited to complete an online discrete-choice experiment. Respondents were asked to choose between pairs of hypothetical medications for virtual patients. Each hypothetical medication was described based on predefined key attributes: time until first sre, time until worsening of pain, medication-related annual risk of osteonecrosis of the jaw (ONJ), medication-related annual risk of renal impairment, and mode of administration. A random-parameters logit model was used to analyze the choices between hypothetical medications and thus infer physician preferences for medication attributes. Results: Responses from the 200 physicians who completed the discrete-choice experiment suggested that months until first sre, risk of renal impairment, and months until worsening of pain were considered the most important attributes affecting choice of BTA. The annual risk of ONJ was considered the least important attribute. Conclusions: When making treatment decisions about the choice of bta for patients with bone metastasis from solid tumours, delaying sres and worsening of pain, and reducing the risk of renal impairment are primary considerations for physicians in Canada.
Keywords: bone metastases; skeletal-related events; physician preferences; conjoint analysis; discrete-choice experiments; bone-targeted agents bone metastases; skeletal-related events; physician preferences; conjoint analysis; discrete-choice experiments; bone-targeted agents

Share and Cite

MDPI and ACS Style

Arellano, J.; González, J.M.; Qian, Y.; Habib, M.; Mohamed, A.F.; Gatta, F.; Hauber, A.B.; Posner, J.; Califaretti, N.; Chow, E. Physician Preferences for Bone Metastasis Drug Therapy in Canada. Curr. Oncol. 2015, 22, 342-348. https://doi.org/10.3747/co.22.2380

AMA Style

Arellano J, González JM, Qian Y, Habib M, Mohamed AF, Gatta F, Hauber AB, Posner J, Califaretti N, Chow E. Physician Preferences for Bone Metastasis Drug Therapy in Canada. Current Oncology. 2015; 22(5):342-348. https://doi.org/10.3747/co.22.2380

Chicago/Turabian Style

Arellano, J., J.M. González, Y. Qian, M. Habib, A.F. Mohamed, F. Gatta, A.B. Hauber, J. Posner, N. Califaretti, and E. Chow. 2015. "Physician Preferences for Bone Metastasis Drug Therapy in Canada" Current Oncology 22, no. 5: 342-348. https://doi.org/10.3747/co.22.2380

APA Style

Arellano, J., González, J. M., Qian, Y., Habib, M., Mohamed, A. F., Gatta, F., Hauber, A. B., Posner, J., Califaretti, N., & Chow, E. (2015). Physician Preferences for Bone Metastasis Drug Therapy in Canada. Current Oncology, 22(5), 342-348. https://doi.org/10.3747/co.22.2380

Article Metrics

Back to TopTop